Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00383266 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00383266: Clinical Trial Phase 2 study, sponsored by Washington University School of Medicine.
NCT00383266 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00383266, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a study of an investigational agent, pemetrexed, in combination with a standard chemotherapy drug, carboplatin, for treatment of patients with metastatic esophageal cancer.
Primary Outcome
* Overall response rate = complete response (CR) + partial response (PR) using RECIST. * CR=disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level * PR=at least a 30% decrease in the sum of the longest diameter (LD) of the target lesions taking as reference the baseline sum LD
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Why NCT00383266 stopped before completion
NCT00383266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT00383266 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00383266 about?
NCT00383266 is a clinical study titled "A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer". This is a study of an investigational agent, pemetrexed, in combination with a standard chemotherapy drug, carboplatin, for treatment of patients with metastatic esophageal cancer.
What is the current status of trial NCT00383266?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2006-10. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00383266?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00383266?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00383266's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia